obesity

Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday. The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs. The Eli Lilly Analyst: Analyst...

Palatin Technologies Inc. (NYSE:PTN) on Monday reported topline data with co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide. Eli Lilly And Co’s (NYSE:LLY) tirzepatide is available as...

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...

Pershing Square Capital CEO Bill Ackman sparked controversy on social media platform X by criticizing the Coca-Cola Co. (NYSE:KO) and PepsiCo Inc. (NYSE:PEP) over their marketing practices, comparing them to tobacco companies and linking them to obesity and diabetes concerns. What Happened: Ackman...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:AMGN) new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/...

On Tuesday, Amgen Inc (NASDAQ:AMGN) stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients. The company said that MariTide demonstrated up to ~20% average weight...

Eli Lilly & Co. (NYSE:LLY) shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%. The pharmaceutical giant, which ranks 11th by market capitalization in the S&P 500 and holds the...

The United States may have reached a turning point in its decades-long battle against obesity. Recent data suggests that 2020 could mark the year when obesity rates in America not only peaked but began to decline, echoing the historic moment in 1963 when cigarette sales in the U.S. hit their apex...

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) experienced a severe drop on Friday, plummeting almost 60% from $52 to $21, as competitor Novo Nordisk (NYSE:NVO) published trial results for monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist. Novo Nordisk shares also traded down roughly 5.5...

Editor's Note: This article has been corrected to properly attribute the information to Dr. Benjamin Caplan, rather than a study that appeared in the American Journal of Medicine. Benzinga takes full responsibility for the error and apologizes to Dr. Caplan and our readers. A recent study published...

Novo Nordisk A/S. (NYSE:NVO) has found that its “miracle” weight loss drug used for diabetes, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. What Happened: A study conducted at the University of Oxford revealed that patients who used...

Novo Nordisk‘s (NYSE:NVO) weight loss drug Wegovy has received approval in China, representing a notable achievement for the Danish pharmaceutical firm. In response to this announcement, the company’s U.S.-listed stock is experiencing a surge of over 2% in pre-market trading on Tuesday...

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo...

The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from Novo Nordisk (NYSE:NVO) and Eli Lilly...

The Structure Therapeutics (NASDAQ:GPCR) stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. What Happened: JPMorgan has initiated coverage of Structure Therapeutics, a biotech company, with an “Overweight...